PHIO - Phio Pharmaceuticals Corp. News

HC Wainwright & Co. Reiterates Buy on Phio Pharmaceuticals, Maintains $14 Price Target

HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharmaceuticals (NASDAQ:PHIO) with

Phio Pharmaceuticals Receives US Notice Of Allowance For Patent Covering PH-894, Further Strengtheni

PH-894 protection for chemical structure, genetic sequencing and broad application for proliferative

Phio Pharmaceuticals Secures U.S. Notice of Allowance for INTASYL Composition Selectively Targeting

King of Prussia, Pennsylvania--(Newsfile Corp. - August 11, 2026) - Phio Pharmaceuticals Corp. (NASD

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Strategic milestone advancements for lead clinical candidate PH-762 Initiation of commercial scale A

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Com

Live Presentation and Q&A: Tuesday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual No

Live Presentation and Q&A: Thursday, July 28, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfil

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

Brings extensive experience in patient care, dermatologic research and commercialization King of Pru

Phio Pharmaceuticals Announces Multiple Favorable Patent Actions Encompassing Three Notices Of Allow

The company has received multiple favorable patent actions encompassing three notices of allowance

Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decisio

Securing additional patent protection in the United States, Canada, and Japan for INTASYL Compounds

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual No

Live Presentation and Q&A: Tuesday, June 30, 2026 12 PM EDT King of Prussia, Pennsylvania--(Newsfile

Phio Pharma To Discuss siRNA Oncology At Force Family Office Fireside Chat; INTASYL Program Position

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company develop

Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fi

King of Prussia, Pennsylvania--(Newsfile Corp. - June 25, 2026) - Phio Pharmaceuticals Corp. (NASDAQ

Phio Pharmaceuticals Commences Manufacturing The First Commercial-scale Batch Of PH-762 Drug Substan

Phio entered into a comprehensive drug substance services agreement with Nitto Denko Avecia, Inc. in

Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762

Nitto Denko Avecia begins first commercial-scale cGMP production of PH-762 drug substance Newly manu

Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - June 18, 2026) - Phio Pharmaceuticals Corp. (NASDAQ

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual No

King of Prussia, Pennsylvania--(Newsfile Corp. - May 26, 2026) - Phio Pharmaceuticals Corp. (NASDAQ:

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Phio Pharmaceuticals Announces "Innovations in Skin Cancer Treatment and Prevention" in a Fireside C

Live virtual fireside chat - investors, advisors, and life sciences analysts invited to attendFeatur

Phio Pharma Q1 EPS $(0.34) Misses $(0.23) Estimate

Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.34) per share which missed the analyst co

Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

Completion of Lead Clinical Candidate PH-762 Dose Escalation Trial for Treatment of Skin Cancer with

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual No

King of Prussia, Pennsylvania--(Newsfile Corp. - April 23, 2026) - Phio Pharmaceuticals Corp. (NASDA

Phio Pharma To Discuss Cancer Drug Progress In Upcoming Investor Chat, Highlights Early Results For

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company develop

Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat

Phio invites investors, advisors and analysts with an interest in the life sciences sector to attend

Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026

King of Prussia, Pennsylvania--(Newsfile Corp. - April 9, 2026) - Phio Pharmaceuticals Corp. (NASDAQ

Phio Pharmaceuticals Enters Into A cGMP Drug Product Manufacturing Services Agreement With A US Manu

Recent Company Highlights Phio's lead clinical candidate, PH-762, is being evaluated as an intra

Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-76

A Critical Next Step in Advancing Phio's PH-762 Program to Treat Cutaneous Carcinomas King of Prussi

defenseworld.net

Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO)

Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and Galectin Therapeutics (NASDAQ: GALT - Get

defenseworld.net

Head-To-Head Contrast: ProKidney (NASDAQ:PROK) & Phio Pharmaceuticals (NASDAQ:PHIO)

Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and ProKidney (NASDAQ: PROK - Get Free Report)

Phio Pharmaceuticals Announces Positive Clinical Data Supporting Treatment Research For Specific Car

The presentation, entitled "PD-1 Directed Intratumoral Immunotherapy: Results of an Escalating D

Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical

Prestigious Late-Breaking Research Session Positions PH-762 as a Promising New PD-1 Directed Immunot

12 Health Care Stocks Moving In Wednesday's Intraday Session

12 Health Care Stocks Moving In Friday's Intraday Session

12 Health Care Stocks Moving In Thursday's After-Market Session

What's Going On With Tiny Cancer Biotech Phio Pharmaceuticals On Thursday?

Phio Pharma stock fell after a recent rally, despite strong Phase 1b trial results showing an 85% re

12 Health Care Stocks Moving In Wednesday's Intraday Session

HC Wainwright & Co. Reiterates Buy on Phio Pharma, Maintains $14 Price Target

HC Wainwright & Co. analyst Matthew Keller reiterates Phio Pharma (NASDAQ:PHIO) with a Buy an

12 Health Care Stocks Moving In Tuesday's Intraday Session

Cancer Biotech Phio Pharmaceuticals Stock Surges As Trial Shows Tumor Clearance At Highest Dose In S

Phio Pharmaceuticals shares rise after Phase 1b data shows strong safety and tumor clearance for its

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

Phio Pharmaceuticals Data From Phase 1b Dose Escalation Clinical Study Shows 14 Participants To Be P

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company develop

Phio Pharmaceuticals' Nonclinical Protocol For PH-762 Accepted By FDA; Toxicology Study Set To Begin

Nonclinical protocol study design accepted by FDAStudy to commence in First Quarter 2026King of Prus

Phio Pharmaceuticals Completes Enrollment In Phase 1b Trial Of PH-762 siRNA Cancer Therapy

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company develop

Phio Pharma Q3 EPS $(0.44) Misses $(0.40) Estimate

Phio Pharma (NASDAQ:PHIO) reported quarterly losses of $(0.44) per share which missed the analyst co

12 Health Care Stocks Moving In Thursday's After-Market Session

12 Health Care Stocks Moving In Monday's After-Market Session

Phio Pharma Secures $13.4M Through Warrant Exercises Covering 5.66M Shares, Including Reduced $2.05

Phio Pharmaceuticals Corp. (NASDAQ:PHIO), a clinical-stage siRNA biopharmaceutical company developin

Why Is Phio Pharmaceuticals Stock Soaring Today?

Shares of Phio Pharmaceuticals Corp. (NASDAQ: PHIO) are rising Monday after the company provided an

12 Health Care Stocks Moving In Monday's Intraday Session

Phio Pharma Reports 100% Tumor Clearance In Final Dose Group Of Skin Cancer Trial

Phio Pharmaceuticals Corp. (NASDAQ:PHIO) is a clinical-stage siRNA biopharmaceutical company develop